Ali M. Elgindy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali M. Elgindy has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Mohamed Atwa
Department of Pharmacology and Toxicology, College of Pharmacy, Al-Ayen Iraqi University, AUIQ, An Nasiriyah, Iraq
7 shared publications - Aya Mohamed Mustafa
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt
5 shared publications - Mahmoud Abdelrahman Alkabbani
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt
5 shared publications - Riham A. El-Shiekh
Department of Pharmacognosy, Faculty of pharmacy Cairo University Cairo Egypt
5 shared publications - Kawther Magdy Ibrahim
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt
3 shared publications - Manar M. Esmail
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt
3 shared publications
Latest Publications
- Open Access
- 9 January 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (2) , 919-950
From nutrition to therapeutics: the diverse inflammopharmacological and biomedical roles of astaxanthin
Astaxanthin, a xanthophyll carotenoid derived primarily from Hematococcus lacustris , has been proposed as a potent bioactive compound demonstrating wide therapeutic applicability. In addition to its distinct molecular structure, astaxanthin has exceptional antioxidant property, surpassing that of other carotenoids and conventional antioxidants, while also exerting robust anti-inflammatory effects. The present review focuses on the current evidence of the complex multifaceted therapeutic actions of astaxanthin, including cardiovascular protection, neuroprotection, hepatoprotection, renal support, dermatological health, immune modulation, and emerging roles in metabolic disorders, reproductive health, and cancer prevention. Mechanistic insights highlight its potential to control key molecular mechanisms, including the NF-κB, Nrf2, MAPK, and TGF-β/Smad pathways, alongside the enhancement of endogenous antioxidant defenses. Preclinical and clinical findings have demonstrated benefits in conditions such as atherosclerosis, myocardial ischemia, nonalcoholic fatty liver disease, hypertension, Alzheimer’s disease, Parkinson’s disease, and inflammatory skin diseases. By integrating evidence drawn from molecular, experimental, and clinical studies, this review underscores astaxanthin’s potential as a complementary therapeutic agent and functional nutraceutical. The breadth of its bioactivity positions astaxanthin as a promising natural compound for targeted disease prevention and health promotion.
- 9 January 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (2) , 919-950
Open AccessFrom nutrition to therapeutics: the diverse inflammopharmacological and biomedical roles of astaxanthin
Astaxanthin, a xanthophyll carotenoid derived primarily from Hematococcus lacustris , has been proposed as a potent bioactive compound demonstrating wide therapeutic applicability. In addition to its distinct molecular structure, astaxanthin has exceptional antioxidant property, surpassing that of other carotenoids and conventional antioxidants, while also exerting robust anti-inflammatory effects. The present review focuses on the current evidence of the complex multifaceted therapeutic actions of astaxanthin, including cardiovascular protection, neuroprotection, hepatoprotection, renal support, dermatological health, immune modulation, and emerging roles in metabolic disorders, reproductive health, and cancer prevention. Mechanistic insights highlight its potential to control key molecular mechanisms, including the NF-κB, Nrf2, MAPK, and TGF-β/Smad pathways, alongside the enhancement of endogenous antioxidant defenses. Preclinical and clinical findings have demonstrated benefits in conditions such as atherosclerosis, myocardial ischemia, nonalcoholic fatty liver disease, hypertension, Alzheimer’s disease, Parkinson’s disease, and inflammatory skin diseases. By integrating evidence drawn from molecular, experimental, and clinical studies, this review underscores astaxanthin’s potential as a complementary therapeutic agent and functional nutraceutical. The breadth of its bioactivity positions astaxanthin as a promising natural compound for targeted disease prevention and health promotion.
- Open Access
- 26 December 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (6) , 8245-8262
Neuroprotection by canagliflozin in a Huntington’s disease model: role of HIF-1α and PI3K/AKT signaling
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and metabolic dysfunction, largely driven by mitochondrial impairment and defective energy metabolism. Altered signaling through hypoxia-inducible factor-1α (HIF-1α) and PI3K/AKT cascades contributes to neuronal vulnerability. Canagliflozin (Cana), a sodium–glucose cotransporter-2 inhibitor, has shown cognitive benefits in experimental studies. Here, we evaluated whether Cana mitigates 3-nitropropionic acid (3NP, 10 mg/kg, i.p., 14 days)-induced HD-like neurotoxicity in rats. Animals received Cana (5 or 10 mg/kg, p.o.) daily for 14 days, followed by behavioral assessments (open-field, Morris water maze, novel object recognition), histopathology, immunohistochemistry, and biochemical assays. Cana treatment significantly improved locomotor and memory performance, reduced striatal histopathological alterations, and attenuated GFAP immunoreactivity. Mechanistically, Cana upregulated HIF-1α and downstream GLUT1/GLUT3/HKII, restored PI3K/AKT/CREB/BDNF signaling, and enhanced SIRT1/PGC-1α/Nrf2 antioxidant responses, while suppressing inflammatory mediators and caspase-3 activation. These findings highlight Cana as a promising disease-modifying strategy for HD by targeting both energy metabolism and pro-survival pathways.
- 26 December 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (6) , 8245-8262
Open AccessNeuroprotection by canagliflozin in a Huntington’s disease model: role of HIF-1α and PI3K/AKT signaling
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and metabolic dysfunction, largely driven by mitochondrial impairment and defective energy metabolism. Altered signaling through hypoxia-inducible factor-1α (HIF-1α) and PI3K/AKT cascades contributes to neuronal vulnerability. Canagliflozin (Cana), a sodium–glucose cotransporter-2 inhibitor, has shown cognitive benefits in experimental studies. Here, we evaluated whether Cana mitigates 3-nitropropionic acid (3NP, 10 mg/kg, i.p., 14 days)-induced HD-like neurotoxicity in rats. Animals received Cana (5 or 10 mg/kg, p.o.) daily for 14 days, followed by behavioral assessments (open-field, Morris water maze, novel object recognition), histopathology, immunohistochemistry, and biochemical assays. Cana treatment significantly improved locomotor and memory performance, reduced striatal histopathological alterations, and attenuated GFAP immunoreactivity. Mechanistically, Cana upregulated HIF-1α and downstream GLUT1/GLUT3/HKII, restored PI3K/AKT/CREB/BDNF signaling, and enhanced SIRT1/PGC-1α/Nrf2 antioxidant responses, while suppressing inflammatory mediators and caspase-3 activation. These findings highlight Cana as a promising disease-modifying strategy for HD by targeting both energy metabolism and pro-survival pathways.
- Open Access
- 16 September 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (10) , 6231-6249
Neuroprotective effects of candesartan in 3-nitropropionic acid-induced Huntington’s disease: modulation of angiotensin and CREB/BDNF/PGC1-α signaling
Renin–Angiotensin System has been implicated in neurodegenerative diseases such as Huntington’s (HD). It is made up of two axes: one is the Angiotensin II Type 1 receptor (AT1R) or Angiotensin II Type 2 receptor (AT2R), while the other is angiotensin-(1-7) [Ang-(1-7)], and Mas receptor; the latter has reported developing a neuroprotective effect; oppositely, AT1R activation has been linked to neurodegenerative diseases. This study aims to elucidate the potential neuroprotective effect of Candesartan (Cand) an AT1R blocker in mitigating neuronal degeneration caused by 3-Nitropropionic acid (3NP) induced HD by revealing the prospective role of Ang II/AT2R/Ang-(1-7)/Mas receptor, CREB/BDNF/PGC1-α besides JNK/c-Jun trajectories, as well as the anti-apoptotic survivin. HD was induced by 3NP (10 mg/kg) for 14 days. Rats received Candesartan (2.5 or 5 mg/kg) for 14 days, after which brain and striatum were isolated for the histopathological, immunohistochemical, and biochemical analysis. Cand displayed significant improvement in the rats’ behavioral tests, enhancing their memory, motor, and cognitive functions induced by 3NP, which was confirmed by the striatal histopathological and immunohistochemical examination of the GFAP. In addition, Cand activated the Ang II/AT2R/Ang-(1-7)/Mas receptor axis. Moreover, Cand stimulated the production of striatal neurotrophic proteins CREB/BDNF/PGC1-α which in turn decreased the levels of inflammatory mediators NF-κB and IL-1β, accompanied by an increase in the antioxidants NQO1 and HO-1 levels. Similarly, Cand led to the inhibition of the JNK/c-Jun with activation of survivin. In conclusion, Candesartan has mitigated the striatal degeneration and mitochondrial dysfunction induced by 3NP through various mechanistic pathways.
- 16 September 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (10) , 6231-6249
Open AccessNeuroprotective effects of candesartan in 3-nitropropionic acid-induced Huntington’s disease: modulation of angiotensin and CREB/BDNF/PGC1-α signaling
Renin–Angiotensin System has been implicated in neurodegenerative diseases such as Huntington’s (HD). It is made up of two axes: one is the Angiotensin II Type 1 receptor (AT1R) or Angiotensin II Type 2 receptor (AT2R), while the other is angiotensin-(1-7) [Ang-(1-7)], and Mas receptor; the latter has reported developing a neuroprotective effect; oppositely, AT1R activation has been linked to neurodegenerative diseases. This study aims to elucidate the potential neuroprotective effect of Candesartan (Cand) an AT1R blocker in mitigating neuronal degeneration caused by 3-Nitropropionic acid (3NP) induced HD by revealing the prospective role of Ang II/AT2R/Ang-(1-7)/Mas receptor, CREB/BDNF/PGC1-α besides JNK/c-Jun trajectories, as well as the anti-apoptotic survivin. HD was induced by 3NP (10 mg/kg) for 14 days. Rats received Candesartan (2.5 or 5 mg/kg) for 14 days, after which brain and striatum were isolated for the histopathological, immunohistochemical, and biochemical analysis. Cand displayed significant improvement in the rats’ behavioral tests, enhancing their memory, motor, and cognitive functions induced by 3NP, which was confirmed by the striatal histopathological and immunohistochemical examination of the GFAP. In addition, Cand activated the Ang II/AT2R/Ang-(1-7)/Mas receptor axis. Moreover, Cand stimulated the production of striatal neurotrophic proteins CREB/BDNF/PGC1-α which in turn decreased the levels of inflammatory mediators NF-κB and IL-1β, accompanied by an increase in the antioxidants NQO1 and HO-1 levels. Similarly, Cand led to the inhibition of the JNK/c-Jun with activation of survivin. In conclusion, Candesartan has mitigated the striatal degeneration and mitochondrial dysfunction induced by 3NP through various mechanistic pathways.
- Open Access
- 21 July 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (7) , 1-28
Targeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise
Psoriasis is a chronic immune-mediated skin disorder characterized by aberrant keratinocyte proliferation, immune cell dysregulation, and sustained inflammation driven by cytokines, such as TNF-α, IL-17, and IL-23. Despite advancements in biologic therapies, limitations related to cost, safety, and resistance have prompted interest in alternative strategies. This review explores the pharmacological basis of natural products as promising anti-psoriatic agents, focusing on compounds with multi-targeted mechanisms including anti-inflammatory, anti-oxidant, anti-proliferative, and immunomodulatory activities. Key phytochemicals, such as curcumin, thymoquinone, glycyrrhizin, and boswellic acids, are examined for their roles in modulating psoriatic pathways like NF-κB, IL-23/Th17 axis, and oxidative stress. Evidence from preclinical and clinical studies highlights their potential in reducing psoriasis area and severity index (PASI) scores, mitigating immune hyperactivity, and enhancing the safety and efficacy of standard therapies. Despite promising outcomes, translational hurdles persist, including extract standardization, pharmacokinetic limitations, and regulatory barriers. The integration of omics-based research and advanced formulation technologies is essential to support the clinical application of these agents. This review underscores the therapeutic potential of natural compounds as viable complements or alternatives in modern psoriasis management.
- 21 July 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (7) , 1-28
Open AccessTargeting psoriatic inflammation with natural compounds: mechanistic insights and therapeutic promise
Psoriasis is a chronic immune-mediated skin disorder characterized by aberrant keratinocyte proliferation, immune cell dysregulation, and sustained inflammation driven by cytokines, such as TNF-α, IL-17, and IL-23. Despite advancements in biologic therapies, limitations related to cost, safety, and resistance have prompted interest in alternative strategies. This review explores the pharmacological basis of natural products as promising anti-psoriatic agents, focusing on compounds with multi-targeted mechanisms including anti-inflammatory, anti-oxidant, anti-proliferative, and immunomodulatory activities. Key phytochemicals, such as curcumin, thymoquinone, glycyrrhizin, and boswellic acids, are examined for their roles in modulating psoriatic pathways like NF-κB, IL-23/Th17 axis, and oxidative stress. Evidence from preclinical and clinical studies highlights their potential in reducing psoriasis area and severity index (PASI) scores, mitigating immune hyperactivity, and enhancing the safety and efficacy of standard therapies. Despite promising outcomes, translational hurdles persist, including extract standardization, pharmacokinetic limitations, and regulatory barriers. The integration of omics-based research and advanced formulation technologies is essential to support the clinical application of these agents. This review underscores the therapeutic potential of natural compounds as viable complements or alternatives in modern psoriasis management.
- Open Access
- 31 March 2025
- Published by Springer Nature in Inflammopharmacology
- p. 1-18
HPLC-HRMS/MS and anti-inflammatory effects of bunya pine resin through multifaceted pathway modulation: NUMB/NOTCH1/HES1/mTOR/ PI3K/HMGB1 signaling cascades
The oleoresins of the Araucaria bidwillii Hook. (A.B.) are commonly used for the treatment of several conditions. However, the full phytochemical profile of its active compounds and its mechanism of action to protect the liver from toxicity remain unclear. The purpose of this research was to investigate the complete set of data relating to the A.B. active metabolites and explore the hepatoprotective properties of AB ethanolic extract on MTX-induced liver injury mainly due to its anti-inflammatory role. Hepatic markers, oxidative stress, inflammatory mediators, the NOTCH/NICD signaling cascade, HES1 expression, HMGB1/TLR4, and the PI3K/mTOR axis were assessed. HPLC-HRMS/MS analysis of A.B. led to the annotation of fifteen compounds from different classes, where diterpenes are the dominant class. Additionally, A.B. (100 and 200 mg/kg) significantly decreased hepatic markers, oxidative stress, and inflammatory mediators. Moreover, the extract significantly increased NOTCH pathway stimulation and HES1 expression, accompanied by a significant decline in the NUMB and HMGB1/TLR4 axes. In addition, it significantly inhibited the PI3K/mTOR pathway, with a prominent effect at the higher dose. This study presents A.B. as a promising hepatoprotective agent through stimulation of the NOTCH pathway and inhibition of the HMGB1/TLR4 pathway, as well as the PI3K/mTOR/NF-κB axis, besides its antioxidant and anti-inflammatory effects.
- 31 March 2025
- Published by Springer Nature in Inflammopharmacology
- p. 1-18
Open AccessHPLC-HRMS/MS and anti-inflammatory effects of bunya pine resin through multifaceted pathway modulation: NUMB/NOTCH1/HES1/mTOR/ PI3K/HMGB1 signaling cascades
The oleoresins of the Araucaria bidwillii Hook. (A.B.) are commonly used for the treatment of several conditions. However, the full phytochemical profile of its active compounds and its mechanism of action to protect the liver from toxicity remain unclear. The purpose of this research was to investigate the complete set of data relating to the A.B. active metabolites and explore the hepatoprotective properties of AB ethanolic extract on MTX-induced liver injury mainly due to its anti-inflammatory role. Hepatic markers, oxidative stress, inflammatory mediators, the NOTCH/NICD signaling cascade, HES1 expression, HMGB1/TLR4, and the PI3K/mTOR axis were assessed. HPLC-HRMS/MS analysis of A.B. led to the annotation of fifteen compounds from different classes, where diterpenes are the dominant class. Additionally, A.B. (100 and 200 mg/kg) significantly decreased hepatic markers, oxidative stress, and inflammatory mediators. Moreover, the extract significantly increased NOTCH pathway stimulation and HES1 expression, accompanied by a significant decline in the NUMB and HMGB1/TLR4 axes. In addition, it significantly inhibited the PI3K/mTOR pathway, with a prominent effect at the higher dose. This study presents A.B. as a promising hepatoprotective agent through stimulation of the NOTCH pathway and inhibition of the HMGB1/TLR4 pathway, as well as the PI3K/mTOR/NF-κB axis, besides its antioxidant and anti-inflammatory effects.
- Open Access
- 1 March 2025
- Published by Egyptian Knowledge Bank in Records of Pharmaceutical and Biomedical Sciences
- Vol. 9 (3) , 59-69
Molecular and Cellular Insights into Huntington’s Disease Pathophysiology
Huntington’s disease (HD) is a fatal, inherited neurodegenerative disorder characterized by progressive motor dysfunction, cognitive deterioration, and psychiatric symptoms. It primarily affects the basal ganglia, especially the striatum, resulting in both structural and functional abnormalities. At the molecular level, the disease is driven by a toxic gain-of-function mutation in the huntingtin gene, leading to intracellular dysfunctions including protein misfolding, impaired axonal transport, transcriptional dysregulation, mitochondrial failure, oxidative stress, and excitotoxicity. This review provides a comprehensive overview of HD pathophysiology, emphasizing the mechanisms underlying striatal vulnerability and basal ganglia circuit disruption. Particular attention is given to mitochondrial dysfunction, oxidative damage, neuroinflammation, and the role of the renin-angiotensin system (RAS), including the emerging neuroprotective potential of the ACE2/Ang-(1–7)/Mas receptor axis. Insights into these interconnected pathways not only deepen our understanding of disease progression but also highlight novel therapeutic targets. Despite substantial advances in elucidating HD pathology, a cure remains elusive, reinforcing the urgency of exploring targeted interventions that may mitigate neurodegeneration and enhance patient outcomes
- 1 March 2025
- Published by Egyptian Knowledge Bank in Records of Pharmaceutical and Biomedical Sciences
- Vol. 9 (3) , 59-69
Open AccessMolecular and Cellular Insights into Huntington’s Disease Pathophysiology
Huntington’s disease (HD) is a fatal, inherited neurodegenerative disorder characterized by progressive motor dysfunction, cognitive deterioration, and psychiatric symptoms. It primarily affects the basal ganglia, especially the striatum, resulting in both structural and functional abnormalities. At the molecular level, the disease is driven by a toxic gain-of-function mutation in the huntingtin gene, leading to intracellular dysfunctions including protein misfolding, impaired axonal transport, transcriptional dysregulation, mitochondrial failure, oxidative stress, and excitotoxicity. This review provides a comprehensive overview of HD pathophysiology, emphasizing the mechanisms underlying striatal vulnerability and basal ganglia circuit disruption. Particular attention is given to mitochondrial dysfunction, oxidative damage, neuroinflammation, and the role of the renin-angiotensin system (RAS), including the emerging neuroprotective potential of the ACE2/Ang-(1–7)/Mas receptor axis. Insights into these interconnected pathways not only deepen our understanding of disease progression but also highlight novel therapeutic targets. Despite substantial advances in elucidating HD pathology, a cure remains elusive, reinforcing the urgency of exploring targeted interventions that may mitigate neurodegeneration and enhance patient outcomes
- Top Cited PapersOpen Access
- 5 November 2024
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (1) , 163-182
Therapeutic applications of eucalyptus essential oils
Eucalyptus essential oils (EEOs) have gained significant attention recently anticipated to their broad range of prospective benefits in various biological applications. They have been proven to have strong antibacterial properties against a variety of bacteria, fungi, and viruses. This makes them valuable in combating infections and supporting overall hygiene. The active compounds present in these oils can help alleviate inflammation, making them valuable in addressing inflammatory conditions such as arthritis, respiratory ailments, and skin disorders. Respiratory health benefits are another prominent aspect of EEOs. Inhalation of these oils can help promote clear airways, relieve congestion, and ease symptoms of respiratory conditions like coughs, colds, and sinusitis. They are often utilized in inhalation therapies and chest rubs. They can be used topically or in massage oils to alleviate muscle and joint pain. Furthermore, these oils have shown potential in supporting wound healing. Their antimicrobial activity helps prevent infection, while their anti-inflammatory and analgesic properties contribute to reducing inflammation and pain associated with wounds. In aromatherapy, EEOs are renowned for their invigorating and uplifting qualities, promoting mental clarity, relaxation, and stress relief. Overall, EEOs hold great promise in biological applications, offering a natural and versatile approach to promote health and well-being. Continued research and exploration of their therapeutic potential will further unveil their benefits and broaden their applications in various fields.
- 5 November 2024
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (1) , 163-182
Top Cited PapersOpen AccessTherapeutic applications of eucalyptus essential oils
Eucalyptus essential oils (EEOs) have gained significant attention recently anticipated to their broad range of prospective benefits in various biological applications. They have been proven to have strong antibacterial properties against a variety of bacteria, fungi, and viruses. This makes them valuable in combating infections and supporting overall hygiene. The active compounds present in these oils can help alleviate inflammation, making them valuable in addressing inflammatory conditions such as arthritis, respiratory ailments, and skin disorders. Respiratory health benefits are another prominent aspect of EEOs. Inhalation of these oils can help promote clear airways, relieve congestion, and ease symptoms of respiratory conditions like coughs, colds, and sinusitis. They are often utilized in inhalation therapies and chest rubs. They can be used topically or in massage oils to alleviate muscle and joint pain. Furthermore, these oils have shown potential in supporting wound healing. Their antimicrobial activity helps prevent infection, while their anti-inflammatory and analgesic properties contribute to reducing inflammation and pain associated with wounds. In aromatherapy, EEOs are renowned for their invigorating and uplifting qualities, promoting mental clarity, relaxation, and stress relief. Overall, EEOs hold great promise in biological applications, offering a natural and versatile approach to promote health and well-being. Continued research and exploration of their therapeutic potential will further unveil their benefits and broaden their applications in various fields.
- Open Access
- 22 July 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 970
A First Metabolite Analysis of Norfolk Island Pine Resin and Its Hepatoprotective Potential to Alleviate Methotrexate (MTX)-Induced Hepatic Injury
Drug-induced liver injury (DILI) represents a significant clinical challenge characterized by hepatic dysfunction following exposure to diverse medications. Methotrexate (MTX) is a cornerstone in treating various cancers and autoimmune disorders. However, the clinical utility of MTX is overshadowed by its ability to induce hepatotoxicity. The current study aims to elucidate the hepatoprotective effect of the alcoholic extract of Egyptian Araucaria heterophylla resin (AHR) on MTX-induced liver injury in rats. AHR (100 and 200 mg/kg) significantly decreased hepatic markers (AST, ALT, and ALP), accompanied by an elevation in the antioxidant’s markers (SOD, HO-1, and NQO1). AHR extract also significantly inhibited the TGF-β/NF-κB signaling pathway as well as the downstream cascade (IL-6, JAK, STAT-3, and cyclin D). The extract significantly reduced the expression of VEGF and p38 with an elevation in the BCL2 levels, in addition to a significant decrease in the IL-1β and TNF-α levels, with a prominent effect at a high dose (200 mg/kg). Using LC-HRMS/MS analysis, a total of 43 metabolites were tentatively identified, and diterpenes were the major class. This study presents AHR as a promising hepatoprotective agent through inhibition of the TGF-β/NF-κB and JAK/STAT3 pathways, besides its antioxidant and anti-inflammatory effects.
- 22 July 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (7) , 970
Open AccessA First Metabolite Analysis of Norfolk Island Pine Resin and Its Hepatoprotective Potential to Alleviate Methotrexate (MTX)-Induced Hepatic Injury
Drug-induced liver injury (DILI) represents a significant clinical challenge characterized by hepatic dysfunction following exposure to diverse medications. Methotrexate (MTX) is a cornerstone in treating various cancers and autoimmune disorders. However, the clinical utility of MTX is overshadowed by its ability to induce hepatotoxicity. The current study aims to elucidate the hepatoprotective effect of the alcoholic extract of Egyptian Araucaria heterophylla resin (AHR) on MTX-induced liver injury in rats. AHR (100 and 200 mg/kg) significantly decreased hepatic markers (AST, ALT, and ALP), accompanied by an elevation in the antioxidant’s markers (SOD, HO-1, and NQO1). AHR extract also significantly inhibited the TGF-β/NF-κB signaling pathway as well as the downstream cascade (IL-6, JAK, STAT-3, and cyclin D). The extract significantly reduced the expression of VEGF and p38 with an elevation in the BCL2 levels, in addition to a significant decrease in the IL-1β and TNF-α levels, with a prominent effect at a high dose (200 mg/kg). Using LC-HRMS/MS analysis, a total of 43 metabolites were tentatively identified, and diterpenes were the major class. This study presents AHR as a promising hepatoprotective agent through inhibition of the TGF-β/NF-κB and JAK/STAT3 pathways, besides its antioxidant and anti-inflammatory effects.